Xeltis prepares for commercial launch after strong aXess trial results - PharmaTimes EU phase 3 data shows major gains in dialysis access performance

#nephrology #Xeltis #aXesstrialresults #aXessclinicaltrial #phase3trial #restorativevascularaccess #vascularaccess #haemodialyisis #primaryendpoint #endstagerenaldisease #haemodiaylisisvascularaccesstreatment #EndogenousTissueRestorationplatform #vascularaccess #dialysispatients
zurl.co/UPkoj